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We studied laxative use and quality of life in persons with opioid-induced constipation (OIC).
417 opioid treated patients with OIC self-administered a cross-sectional online survey.
Abdominal pain and bloating were frequent as was laxative self-management of OIC.
Quality of life was low among those using several laxatives and those using laxatives daily.
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a b s t r a c t
Backgroundandaims:Real-lifedataon laxativeuse inpatients suffering fromopioid-inducedconstipation
(OIC) are very limited, and many OIC patients are only using over the counter laxatives to resolve their
constipation. Our aim was to describe laxative utilization and quality of life in participants in Norway who
ever experienced OIC.
Methods: This was a cross-sectional online survey conducted between 27th of June and 3rd of July 2014
among participants above 18 years with self-reported OIC and who had agreed to receive information
from the pharmacy chain (Boots A/S, Norway). The questionnaire comprised a series of multiple choice,
close-ended, and free text questions on abdominal symptoms, laxative use and health-related quality of
life.
Results: A total of 417 participants met the study eligibility criteria: (1) treated with opioid for a minimum
of 4 weeks, (2) actively accepted participation, and (3) conﬁrmed ever experiencing OIC and in addition
completed the survey. Among the eligible participants, 86% were females, 85% were younger than 60 years
of age, and 57% were currently suffering OIC. More than half of the currently constipated participants were
experiencing moderate to very severe abdominal bloating (63%), abdominal pain (55%) and/or pain during
bowel movement (50%). Less than every fourth participant (23%) had consulted health care professionals
(HCPs) about their constipation. Up to 39% reported that they handled their OIC by self-management,
e.g., bought laxative, reduced the dose and/or changed opioid without consulting HCP or pharmacy. Less
than half (48%) of the laxative users were satisﬁed with the laxative they were using to relieve their
constipation. The EQ-5D health-related quality of life score was mean (SD): 0.587 (0.272). Although not
statistically signiﬁcant (p=0.067), there was a tendency of lower quality of life among the participants
who were currently constipated compared with those not currently constipated (difference of mean EQ-
5D: 0.629–0.555=0.074). A signiﬁcantly lower (p=0.001) quality of lifewas found among participantswho
were dissatisﬁed with their laxative [mean (SD): 0.424 (0.350)] than among those who were satisﬁed or
neither satisﬁed nor dissatisﬁed [mean (SD): 0.628 (0.235) and 0.673 (0.155), respectively].
Conclusions: The results suggest a high degree of moderate to very severe abdominal symptoms, a high
degree of self-management of opioid-induced constipation, a low degree of satisfaction with laxative, and
low health-related quality of life of patients suffering from chronic pain necessitating long-term opioid
treatment, subsequent constipation and laxatives use.
Implications: Patients sufferin
two or more laxatives are a vu
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Table 1
Study eligibility criteria.
Opioid therapy ≥4 weeks with
the expectation to continue
for at last 3 months (target
population)
Participants who conﬁrmed used of
one or more of the speciﬁed opioid
therapies:
Tramadol hydrochloride, tramadol
hydrochloride/paracetamol
Oxycodone hydrochloride
Oxycodone hydrochloride, naloxone
Morphine, hydromorphone
hydrochloride, morphine sulphate,
morphine sulphate pentahydrate
Burprenorphine
Methadone hydrochloride
Codein/paracetamol
Ketobemidone
Pethidine hydrochloride
Fentanyl
OIC (criteria for conﬁrmation
of study eligibility)
Participants who respond “yes” to the
question “have you ever experienced
constipations while on opioid therapy
such as less than three BM pr. week,
bloating or pain in abdomen, BM too
hard or straining/squeezing BM”
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2.4. Ethical conductIC: opioid induced constipation; BM: bowel movements.
. Introduction
Constipation is a well-known and common side-effect of opioid
reatment in patients with moderate-to-severe pain. Between 40
nd 70% of chronic opioid users suffer from opioid induced consti-
ation (OIC) [1–5].
A majority of patients experiencing symptoms of OIC, report
hat the OIC has negative impact on their general quality of life
nd every day activities [6–8]. In a recent study, more than 70%
f the patients who receive opioids due to musculoskeletal pain,
eported that they had not been informed about the risk of experi-
ncing/developing OIC as a treatment side-effect [9]. Additionally,
ne-third of the patients had skipped doses, reduced or stopped
heir use of opioid therapy in order to resolve their gastrointestinal
ide effects, resulting in increased experience of pain for more than
0% of these patients [6].
Real-life data on laxative utilization among patients suffering
romOIC are very limited, andmany patients suffering fromOIC are
nly using over the counter laxatives to resolve their constipation.
In this cross-sectional survey study, the aim was to describe
axativeutilization andquality of life inparticipantswhoever expe-
ienced OIC.
. Method
.1. Study design and sample
This is a cross-sectional survey study among participants expe-
iencing self-reported OIC. The online survey was conducted in
ollaboration with a pharmacy chain (Boots A/S, Norway), admin-
stering the survey via e-mail to more than 82,000 individuals who
ad indicated an interest in receiving general information from the
harmacy. Participants had to (1) conﬁrm that they had been on
pioid therapy for a minimum of 4 weeks with an expectation to
ontinue for at last 3 months (to ensure participants were consis-
ently treatedwith opioid e.g. not acute injury or post-surgical use),
2) actively accept participation in the study to get online access to
he self-reportedquestionnaire, and (3) theparticipants had to con-
rm ever experiencing constipation while on opioid therapy. The
tudy eligibility criteria are presented in Table 1.urnal of Pain 11 (2016) 104–110 105
2.2. Data collection
All participants were informed that participation was voluntary
and anonymous, and they gave consent to the collection, use, and
disclosure of their online response. No data were collected that
potentially could identify a person such as date of birth, name or
personal identiﬁcation number. The online survey took approx-
imately 10min to complete and comprised a series of multiple
choice, close-ended, and free text questions which was divided in
two parts, symptoms and treatment and health related quality of
life. Data were collected between 27th of June 2014 and 3rd of July
2014.
Initially, eligible participants were asked if they were currently
experiencing constipation while on opioid therapy, those who
conﬁrmed current constipation were then asked to evaluate the
severity (no, mild, moderate, severe or very severe) of the follow-
ing three common symptoms of OIC: abdominal pain, abdominal
bloating, and pain on/during bowel movements.
Eligible participantswere asked aboutmanagement of theirOIC,
and their responses were categorized into: consulted health care
professional (HCP; e.g., physician or nurse); consulted pharmacy
without contacting HCP; self-management (e.g., bought over-the-
counter laxative, reduced dose of opioid, changed opioid, or other)
without contacting a HCP or pharmacy; or other/did nothing.
Participants who reported that they consulted a HCP or a phar-
macy were then asked if they were advised to buy laxative with or
without a prescription.
• Prescribed laxativeusersweredeﬁnedas thosewhowere advised
by a HCP or pharmacy to buy prescribed laxative.
• Non-prescribed laxative users were deﬁned as those who were
advised byHCP or pharmacy to buy laxativewithout prescription
and those who bought laxative without contacting a HCP or a
pharmacy.
Both prescribed and non-prescribed laxative users were
asked to specify what type of laxatives they bought: macro-
gol 3350/potassiumchloride/sodiumbicarbonate/sodiumchloride,
lactulose, bisacodyl, senna, ispaghula, other. Further, all laxative
users were categorized according to number of different brands of
laxatives used (one laxative, two or more laxatives), frequency of
laxative use (daily; 6–3 days/week; 1–2 days/week; <1 day/week),
and self-rated satisfaction with laxative on a 5-point scale from
very satisﬁed to very dissatisﬁed.
Health related quality of life was assessed bymeans of the Euro-
QOL 5 Dimensions (EQ-5D) [10] which is a validated 5-item health
state descriptive system where full health is one, and zero is equiv-
alent to death (EQ-5D index) and a visual analogue scale (EQ-5D
VAS, range 0–100 from worst to best imaginable health state).
2.3. Statistical methods
Continuous variables are presented as means and standard
deviations and categorical variables as absolute and relative fre-
quencies. Statistical comparisons were made using analysis of
variance (ANOVA) for continuous variables and chi-square test for
categorical variables. The signiﬁcance level is set at 5% but as no
adjustment formultiplicityhasbeenperformedthep-values should
be considered as exploratory.An opinionwas obtained fromRegional Committees forMedical
and Health Research Ethics (REC) in writing (reference number:
106 H.N. Christensen et al. / Scandinavian Jo
Table 2
Characteristics of participants who have experienced OIC, n=417.
Total, n (%)
Gender
Males 58 (13.9)
Females 359 (86.1)
Age, years
18–39 165 (39.6)
40–59 189 (45.3)
≥60 63 (15.1)
Currently constipated
Yes 239 (57.3)
No 178 (42.7)
Management of OIC
Consulted HCP 96 (23.0)
Consulted pharmacy 41 (9.8)
Self-management 162 (38.8)
Other or nothing 118 (28.3)
Use of laxative
No laxative 181 (43.4)
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Two or more laxatives 94 (22.5)
013/2405 D) stating that the project did not need to be submitted
o ethics Committee due to its design and purpose.
. Results
A total of 910 participants conﬁrmed that they had been treated
ith opioids for aminimumof 4weekswith the expectation to con-
inue for at least 3 months. About half of the participants (n=445)
onﬁrmed that they had at some point experienced OIC and there-
ore were eligible for data analysis. Excluding 28 participants who
id not complete the survey, this study counted 417 eligible par-
icipants who completed the ﬁrst part of the survey.
Among the 417 eligible participants who reported ever expe-
ienced OIC, 86% were females and 85% were younger than 60
ears old (Table 2). Further, more than half of the participants
57%) were currently suffering constipation while on opioid ther-
py (Table 2). The participants responded to questions regarding
ow they managed their OIC, and less than every fourth partici-
ant (23%) had consulted health care professional (i.e., physician
r nurse). Thirty-nine percent reported that they handled their OIC
y self-management, e.g., bought laxative, reduced the dose and/or
hanged opioid without consulting HCP or pharmacy. Twenty-
hree percent reported that they had used two or more laxatives,
4% had used one laxative, and 43% had not used laxative.
The most frequently used opioid therapy was
odein/paracetamol followed by tramadol hydrochloride, tra-
adol hydrochloride/paracetamol (Fig. 1). The most frequently
sed laxative was lactulose followed by bisacodyl (Fig. 2).
More than half of the 239 particpants on opioid therapy who
ere currently constipated were experiencing moderate to very
evere symptoms related to OIC. Severe to very severe symp-
oms were observed in 16% suffering from abdominal bloating,
2% suffered from pain during bowel movement, and 8% who
ad abdominal pain. The symptom burden was more prevalent
n currently constipated participants using laxatives compared to
on-laxative users (Fig. 3). The most pronounced difference in
revalence of moderate to very severe symptom was found for
bdominal bloating when comparing participants using no (46%),
ne (64%), and two or more laxatives (90%) (p<0.05).The laxative utilization among the 236 laxative users who ever
xperienced OIC is presented in Table 3. Twelve percent of the
axative users reported that they purchased laxative which was
rescribed by their HCP. Almost two of three (62%) prescribedurnal of Pain 11 (2016) 104–110
laxative users reported that they had tried only one laxative.
However, it was reported that more than one-third (34%) of the
prescribed laxatives users had previously tried non-prescribed lax-
ative. Participants using twoormore laxativeswere generally using
them more frequently than those using only one laxative (daily
use of laxative: 21% and 6%, respectively). Less than half (48%) of
the laxative users were satisﬁed with the laxative they were using,
one-third (34%) were neither satisﬁed or dissatisﬁed, and about
one-fourth (18%) reported that they were dissatisﬁed with the lax-
ative they were using.
The response rate for the second part of the survey decreased
due to technical issues (users of iOS (Ipad and Iphone) were not
able to get access to EQ5-D questionnaire), therefore only 188 of
the eligible participants were able to answer the items on health-
related quality of life. The EQ-5D index and the EQ-5D VAS score
according to currently constipated, use of laxative, prescription,
laxative frequency, and satisfaction are presented in Table 4. The
mean EQ-5D index score was 0.587 (SD: 0.272) and the mean
EQ-5D VAS score was 60.7 (SD: 22.6). Although not statistically sig-
niﬁcant (p=0.067), there was a tendency of lower health-related
quality of life among the participants who were currently consti-
pated compared to those not currently constipated (difference of
means: 0.629–0.555=0.074). The lowest health-related quality of
life was found among participants who were dissatisﬁed with their
laxative (mean EQ-5D index: 0.424; mean EQ-5D VAS score: 46.1),
and statistically signiﬁcant lower than for those who were satisﬁed
and those who were neither satisﬁed nor dissatisﬁed with laxative
(EQ-5D index: p=0.001 and EQ-5D VAS score: p=0.004).
4. Discussion
The results from this cross-sectional survey study amongpartic-
ipants experiencing OIC suggest a high degree of moderate to very
severe abdominal symptoms, a high degree of self-management of
OIC, a relatively low degree of satisfaction with laxatives, and low
health-related quality of life, especially among those using more
laxatives and using laxatives more often.
Our results show that more than half of the currently con-
stipated participants reported having moderate to very severe
abdominal symptoms (i.e., pain in abdomen, pain during bowel
movement, and abdominal bloating). This ﬁnding was similar to
the prevelence of these symptoms reported by Coyne et al. [7] in
a sample of patients recruited from primary care clinics. Some of
these common abdominal symptoms, particularly bloating, might
also occur as side effects of several classes of laxatives [11]. The
high usage of over-the-counter lactulose in Norway is especially an
unfortunate tradition because of its high prevalence of its adverse
effects bloating and abdominal discomfort and even abdominal
pain. Indeed, the symptom burden was more prevalent in laxative
users than innon-laxativeusers inour study, particulary abdominal
bloating among participants who have used two or more laxatives.
However, the relatively high prevalence of these symptoms might
also suggest that for the participants who have used two or more
laxatives the currently utilized laxative therapies may be lacking
in efﬁcacy and tolerability as well as there is a possibility that par-
ticipants who are not using laxatives are undertreating their OIC.
In a recent longitudinal study by Coyne et al. [12] with prospective
data fromUS, Canada, Germany, andUK itwas estimated thatmore
than one of four participants was a sufﬁcient laxative user but at
the same time inadequate laxative responders, deﬁned as <3 bowel
movements or ≥1 moderate to very severe constipation symptom.Self-management of OIC was frequent among the participants
in our study. More than two out of ﬁve participants reported that
in order to handle their OIC they had bought laxative, reduced the
daily dose and/or changed opioid without consulting their HCP or
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big. 1. Frequency of different types of opioid therapy used among participant
ide/paracetamol. b Morphine, hydromorphone hydrochloride, morphine sulphate,
harmacy, which is consistentwith the proportion reported by Bell
t al. (35%) [6] and Cook et al. (27%) [13]. In a recent Danish cross-
ectional study among patients ﬁlling prescriptions for opioids at
community pharmacy, Pottegård et al. [9] concluded that only
ew of the participants (28%) recalled having had information on
otential constipation caused by opioid and having received any
ecommendation on how to use laxatives to prevent constipation.
ig. 2. Frequencyof different types of laxatives used amongparticipantswhoever experien
icarbonate/sodium chloride.ever experienced OIC, n=417. a Tramadolhydrochloride, tramadol hydrochlo-
hine sulphate pentahydrate.
The fact that relatively few (23%) of the participants in our study
had consulted their physician or nurse regarding how to manage
their OIC imply that they might be unaware of recent advances in
therapeutic approaches for OIC tomanage and prevent OICwithout
compromising analgesic efﬁcacy [14].
Furthermore, our results show that less than half (48%) of
the laxative users were satisﬁed with their laxative and almost
cedOIC andhadused laxative,n=236. a Macrogol 3350/potassiumchloride/sodium
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tig. 3. Prevalence of moderate to very severe symptoms in participants currently
omparison of differences in the prevalence of moderate to very severe symptoms
ne-quarter reported dissatisfaction with the laxative they were
sing, which is consistent with the proportion reported in Cook
t al. [13].
Generally the health-related quality of life (QoL) reported by
he participants in our study was relatively low with a mean EQ-
D index score of 0.587. Our results support the ﬁnding reported
y Brazier et al. [15] in a sample of seven different patient groups
chronic obstructive airways disease, osteoarthritis, irritable bowel
yndrome, lower back pain, leg ulcers, post-menopausal women
nd elderly) in UK, in which the overall mean EQ-5D index score
as 0.586. However, in that study the mean EQ-5D index score
aried across the seven patient/population groups from 0.442 in
steoporosis patients to 0.729 in menopausal women. In the study
y Coyne et al. [7] evaluating currently constipated opioid users,
hemean EQ-5D index score varied across the four country-speciﬁc
amples from 0.270 in UK to 0.610 in Canada. A number of studies
ave shown that patients with constipation report lower QoL than
on-constipated individuals [16–19] which is consistent with our
esults, althoughnot statistically signiﬁcant, participantswhowere
urrently constipated had a lower QoL than those who were not
able 3
reatment utilization among laxative users who ever experienced OIC, n=236.
One laxative (n=142)
Laxatives, n (row %)
Prescribed laxatives 15 (78.9)
Both prescribed and non-prescribed laxative 3 (30.0)
Non-prescribed laxatives 124 (59.9)
Laxative frequency, n (column %)
Daily 9 (6.3)
6–3 days/week 19 (13.4)
1–2 days/week 25 (17.6)
<1 day/week 89 (62.7)
Satisfaction with laxative, n (column %)
Satisﬁed 72 (50.7)
Neither satisﬁed or dissatisﬁed 48 (33.8)
Dissatisﬁed 22 (15.5)
* p-Value for comparison of differences in the distribution of treatment utilization (lax
wo or more laxatives.ipated while on opioid therapy according to laxative use, n=239. p-Value give for
en participants with no, one, two or more laxatives.
currently constipated (mean EQ-5D index score 0.555 and 0.629,
respectively). In addition, our study adds to the literature, that the
lowest QoL was found among participants who were dissatisﬁed
with their laxative and participants who used laxatives every day
(mean EQ-5D index score 0.424 and 0.497, respectively). Similar
patterns were reﬂected by the mean EQ-5D VAS.
This patient group undoubtedly will beneﬁt from more speciﬁc
therapy that is now being introduced. Peripherally acting opioid
receptor antagonist (PAMORAs) has recently been documented to
be effective and safe for this group of unfortunate chronic pain
patients needing opioid for their pain condition [20]. Such drugs
will avoid the extra burden imposed on chronic pain patients who
frequentlyhavehad touse twoormore types of laxativeswith extra
burden of side-effects/adverse effects of such laxatives.
4.1. Limitations and strengthsAswithother surveybasedevaluations, thepresent study comes
with some limitations to be taken into account when interpreting
the results.
Two or more laxatives (n=94) Total (n=236) p-Value*
0.037
4 (21.1) 19 (100)
7 (70.0) 10 (100)
83 (40.1) 207 (100)
0.001
20 (21.3) 29 (12.3)
9 (9.6) 28 (11.9)
24 (25.5) 49 (20.8)
41 (43.6) 130 (55.1)
0.388
42 (44.7) 114 (48.3)
31 (33.0) 79 (33.5)
21 (22.3) 43 (18.2)
ative prescription, frequency and satisfaction) between participants with no, one,
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Table 4
Quality of life (EQ-5D index and VAS score) among participants who ever experienced OIC according to currently constipated, use of laxative, prescription, laxative frequency,
satisfaction.
n EQ-5D index p-Value* EQ-5D VAS score p-Value*
Mean (SD) Mean (SD)
Total 188 0.587 (0.272) 60.7 (22.6)
Currently constipated 0.067 0.206
Yes 107 0.555 (0.296) 58.9 (22.6)
No 81 0.629 (0.231) 63.1 (22.6)
Use of laxative 0.422 0.057
No laxative 79 0.566 (0.292) 61.7 (23.7)
One laxative 70 0.621 (0.271) 63.8 (21.9)
Two or more laxatives 39 0.568 (0.228) 53.3 (20.6)
Prescription 0.775 0.153
Prescribed 10 0.636 (0.409) 72.6 (26.8)
Both prescribed and non-prescribed 4 0.671 (0.219) 54.8 (34.1)
Non-prescribed 95 0.596 (0.240) 58.9 (20.7)
Laxative frequency 0.448 0.004
Daily 13 0.497 (0.217) 40.7 (22.2)
6–3 days/week 12 0.626 (0.240) 59.5 (19.4)
1–2 days/week 20 0.636 (0.232) 67.8 (21.7)
<1 day/week 64 0.608 (0.273) 61.6 (20.6)
Satisfaction with laxative 0.001 0.004
Satisﬁed with laxative 56 0.628 (0.235) 62.3 (22.6)
Neither satisﬁed or dissatisﬁed with laxative 32 0.673 (0.155) 65.2 (17.8)
Dissatisﬁed with laxative 21 0.424 (0.350) 46.1 (21.1)
SD: standard deviation; VAS: Visual Analogue Scale (0–100), lower score indicate worse health state; EQ-5D: EuroQoL 5 dimension index (0–1, with 1= full health), lower
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* p-Value for comparison of means in quality of life (EQ-5D index and VAS score) b
rescription, laxative frequency, satisfaction).
First, we were unable to compare the observed use of laxative
mong patients treated with opioids to an age-matched control
roup not treated with opioids.
Second, our study sample was drawn from an online database
stablished by a pharmacy chain (Boots A/S, Norway) which could
avebiased the sample towardsparticipantshavingagreater famil-
arity with the Internet and interest in receiving information from
he pharmacy. Although, the age and gender distribution were
kewed in favour of younger and female participants, potentially
nferring low generalizability and external validity, the results
till are well in accordance with previous studies on symp-
om burden, self-management, and quality of life in relation to
IC.
Third, the questions, except of EQ-5D, were deﬁned for the
resent study only, and were thus not validated or standard-
zed. Also, data analyzed in this study was based exclusively
n self-report and may be subject to inaccuracy or recall
ias.
Fourth, the participants may be taking other medications, have
imited mobility or have dietary habits that contribute to constipa-
ion. Therefore, it may not be certain that the OIC symptoms found
n this study are only related to opioids.
This study also comes with strengths, not the least the use of
n anonymized self-administration questionnaire. This may have
llowed a more honest response to sensitive questions related to
ymptoms and self-management of constipation as opposed to
n interviewer-administration questionnaire, which may induce
social desirability response bias where the respondent seeks
o please the interviewer. Further, since there are no registries
n the Nordic countries capturing over the counter drug use,
onducting the study via a pharmacy chain database enabled
ssessment of utilization of these types of easily accessible laxa-
ives. In addition, this study not only sheds light on the prevalence
nd use of laxative but also explore aspects of symptoms and
ealth-related quality of life in both non-laxative and laxative
sers.en participants with different characteristics (currently constipated, use of laxative,
5. Conclusions and implications
The results from this cross-sectional survey study amongpartic-
ipants experiencing OIC suggest a high degree of moderate to very
severe abdominal symptoms, a high degree of self-management
of OIC, a low degree of satisfaction with laxatives, and low
health-related quality of life of patients suffering from chronic
pain necessitating long-term opioid treatment. This implies that
patients suffering from OIC with low quality of life and remaining
symptoms despite use of two or more laxative are a vulnerable
patient group in need of optimized healthcare management, who
also might beneﬁt from more speciﬁc and innovative therapy.
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